1,653
+1.47%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Japan Lifeline Co
Its shares trade on Tokyo Stock Exchange under the ticker 7575.T. It has been listed since 8 December 1997. In the fiscal year to 31 March 2026, it reported revenue of ¥59.19bn and net income of ¥9.35bn. At that date it held total assets of ¥80.21bn and shareholders' equity of ¥65.90bn.
Japan Lifeline Co., Ltd. engages in the import, development, production, and distribution of medical devices. The company is headquartered in Shinagawa-Ku, Tokyo-To. The firm is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Dec 1997
- Employees
- 1,074
- Website
- jll.co.jp ↗
Leadership
Pay as last reported
- Mr. Keisuke SuzukiPresident, Chief Executive Officer, Representative Director, since 1987
- Mr. Atsuhiro SuzukiVice President, Chief Operating Officer, Representative Director, since 2007
- Mr. Tatsuya MuraseManaging Director, Chief Director of General Business, since 2020
- Mr. Kenji YamadaManaging Director, Chief Director of Administration, since 2013
- Mr. Takeyoshi EgawaSenior Director of Business Administration, Director, since 2022
- Ms. Yumiko HoshibaSenior Director of General Affairs, Director, since 2014
- Mr. Tadashi IdeiChief Senior Director of Pharmaceutical Affairs, Director, since 2013
- Mr. Takashi ItoChief Director of Cardiac Arrhythmia Business, Director, since 2022
- Mr. Toru TakamiyaChief Director of Development Production, Director, since 2013
- Mr. Shogo TakahashiDirector, since 2011
- Mr. Daizo AsariIndependent Director
- Mr. Yoshiaki IkeiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Product Portfolio: Japan Lifeline Co Ltd offers a diverse range of innovative medical devices and equipment, allowing them to cater to different healthcare needs and capitalize on emerging trends, giving them a competitive edge in the market.
- Strong Market Presence: With several years of operation and a well-established brand reputation, Japan Lifeline Co Ltd has managed to secure a significant market share in the healthcare industry, providing them with stability and a loyal customer base.
- Robust Distribution Network: The company has an extensive distribution network that ensures efficient product availability and delivery. This allows them to reach a wider customer base and maintain strong relationships with healthcare providers.
Weaknesses
- Dependence on Domestic Market: Japan Lifeline Co Ltd heavily relies on the domestic market for its revenue, which exposes them to potential risks associated with economic fluctuations, regulatory changes, and market saturation. Diversifying into international markets could mitigate this weakness.
- Limited Product Differentiation: The medical device industry is highly competitive, and Japan Lifeline Co Ltd faces challenges in distinguishing its products from those offered by competitors. Enhancing product features and investing in research and development could help overcome this weakness.
- Dependency on Suppliers: The company relies on a limited number of suppliers for key components required in their medical devices. Any disruption in the supply chain could impact production and delivery schedules, potentially leading to customer dissatisfaction.
Opportunities
- Growing Aging Population: Japan has a rapidly aging population, resulting in increased demand for healthcare services and medical devices. Japan Lifeline Co Ltd can capitalize on this opportunity by developing specialized products and services targeted at elderly care.
- Emerging Markets: Expanding into emerging markets, particularly in Asia and Latin America, can provide Japan Lifeline Co Ltd with tremendous growth opportunities. These markets are witnessing rising healthcare spending and increased adoption of advanced medical technologies.
- Technological Advancements: The continual advancement of medical technology presents opportunities for Japan Lifeline Co Ltd to develop and introduce cutting-edge devices that cater to unmet needs in the healthcare industry. Investing in research and development is crucial for staying ahead of competitors.
Threats
- Intense Competition: The medical device industry is highly competitive, with numerous local and international players vying for market share. Rival companies might introduce similar products or offer competitive pricing, posing challenges for Japan Lifeline Co Ltd.
- Regulatory Constraints: Compliance with stringent regulations and obtaining necessary certifications for medical devices is essential but can be time-consuming and costly. Changes in regulations or non-compliance could disrupt operations and hinder product development.
- Fluctuating Exchange Rates: As Japan Lifeline Co Ltd expands into international markets, fluctuations in exchange rates could impact their costs and profitability. Currency risk management strategies should be implemented to mitigate this threat.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.